McAdam LLC Sells 1,457 Shares of Liquidia Co. (NASDAQ:LQDA)

McAdam LLC trimmed its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 10.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,034 shares of the company’s stock after selling 1,457 shares during the period. McAdam LLC’s holdings in Liquidia were worth $144,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Patient Square Capital LP acquired a new position in Liquidia in the 1st quarter worth $105,942,000. Farallon Capital Management LLC acquired a new position in Liquidia during the first quarter valued at approximately $30,311,000. Vestal Point Capital LP bought a new position in shares of Liquidia in the fourth quarter worth about $12,331,000. Kynam Capital Management LP boosted its holdings in shares of Liquidia by 34.9% during the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after acquiring an additional 698,324 shares in the last quarter. Finally, Jump Financial LLC acquired a new stake in Liquidia during the 4th quarter worth approximately $1,933,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LQDA has been the topic of several recent analyst reports. Bank of America dropped their price target on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $25.00 price objective on shares of Liquidia in a report on Monday, August 19th. HC Wainwright dropped their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday. BTIG Research lowered their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Finally, Oppenheimer began coverage on Liquidia in a research report on Tuesday, June 25th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.14.

Liquidia Stock Performance

NASDAQ LQDA traded up $0.34 on Friday, reaching $9.97. 1,257,390 shares of the company’s stock traded hands, compared to its average volume of 1,003,718. The firm has a market cap of $761.85 million, a price-to-earnings ratio of -6.39 and a beta of 0.32. The stock has a 50 day moving average price of $11.86 and a 200-day moving average price of $13.22. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Insider Buying and Selling at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the sale, the chief financial officer now directly owns 312,389 shares in the company, valued at approximately $3,914,234.17. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the sale, the chief executive officer now owns 818,932 shares in the company, valued at $10,261,217.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 3,906 shares of Liquidia stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $48,942.18. Following the sale, the chief financial officer now owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The disclosure for this sale can be found here. Insiders have sold 21,437 shares of company stock worth $268,549 in the last ninety days. 31.60% of the stock is owned by insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).